Laden...
The Weekend Edition is pulled from the daily Stansberry Digest. The Digest comes free with a subscription to any of our premium products.
| ||||||||||
| One of our favorite whipping boys just received more bad news... For the past several months, wireless carriers Sprint (S) and T-Mobile (TMUS) – the third- and fourth-largest companies in the industry – have been in merger talks. A joint entity would have boasted more than 130 million U.S. subscribers. That still would have come in third behind Verizon (VZ) and AT&T (T), both of which have more than 138 million U.S. subscribers today... But it would have helped to close the gap. However, the deal fell through last weekend... In a joint statement, the companies said they were "unable to find mutually agreeable terms." Essentially, SoftBank (Sprint's parent company) and Deutsche Telekom (T-Mobile's parent company) didn't support the idea. This news should come as no surprise to Stansberry's Investment Advisory subscribers... In the May issue, Porter and his team of analysts explained why they were skeptical the deal would go through. As they wrote...
Porter and his research team recommended shorting the $25 billion company's stock back in February. As they explained to subscribers at that time, Sprint was a profitless and broken business...
And in a clumsy effort to steal customers away from its rivals, Sprint had created a price war in an industry that was already highly competitive. More from that issue...
Worst of all, the company has a huge wall of debt coming due within the next five years. Sprint's debts have nearly doubled since 2010 as it has struggled to keep up with the rest of the wireless industry...
Sprint features the lowest margins in the industry. It doesn't have any profits over the last decade. It has the most debt (and the most debt coming due) of any major wireless carrier. Its network is the lowest-rated and needs the most capital expenditures to maintain. And its cash flows are negative cash flows. So it's easy to see why Porter and his team recommended selling the stock short... So far, Stansberry's Investment Advisory subscribers are up about 30%. And with the potential merger with T-Mobile now off the table, shares are likely headed even lower. Stay tuned... ----------Recommended Link---------
Meanwhile, if you've been with us for long, you know our goal at Stansberry Research is simple: We strive to give you the information we would want if our roles were reversed. Naturally, this information is usually focused on building and protecting your wealth. But this Wednesday, we're going to share something different... Our colleagues Dave Lashmet and Dr. David "Doc" Eifrig are preparing a special presentation that isn't designed to help you make money (though, as you'll see, you could have the chance to make a fortune). Instead, it's designed to show you how to protect yourself and those you love from one of the most devastating diseases on the planet today. You see, Dave and Doc will be sharing the details on an incredible new cancer treatment that could revolutionize health care as we know it... and potentially save the lives of hundreds of thousands of Americans every year. They believe it is going to change medicine forever... And you can be among the first to learn about this astonishing new treatment. It's absolutely free for Stansberry Research readers, but you must pre-register to attend. Click here to learn more and reserve your spot now. Regards, Justin Brill Editor's note: On Wednesday at 8 p.m. Eastern time, our technology and medical experts Dave Lashmet and Dr. David Eifrig are hosting Stansberry Research's first-ever cancer briefing. You'll learn about a breakthrough that could destroy any cancer you or a family member may one day face... and how to make up to 500% in the little-known company behind it. Reserve your spot for this free event here. |
| |||||||||||||||||||||
| Tell us what you think of this content |
| Home | About Us | Resources | Archive | Free Reports | Privacy Policy |
| To unsubscribe from DailyWealth and any associated external offers, click here. Copyright 2017 Stansberry Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry Research, LLC., 1125 N Charles St, Baltimore, MD 21201 LEGAL DISCLAIMER: This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility. Stansberry Research expressly forbids its writers from having a financial interest in any security they recommend to our subscribers. And all Stansberry Research (and affiliated companies) employees and agents must wait 24 hours after an initial trade recommendation is published on the Internet, or 72 hours after a direct mail publication is sent, before acting on that recommendation. You're receiving this email at [email protected]. If you have any questions about your subscription, or would like to change your email settings, please contact Stansberry Research at (888) 261-2693 Monday – Friday between 9:00 AM and 5:00 PM Eastern Time. Or if calling internationally, please call 443-839-0986. Stansberry Research, 1125 N Charles St, Baltimore, MD 21201, USA. If you wish to contact us, please do not reply to this message but instead go to [email protected]. Replies to this message will not be read or responded to. The law prohibits us from giving individual and personal investment advice. We are unable to respond to emails and phone calls requesting that type of information. |
Laden...
Laden...
